Dr Reddys Naproxen Sodium Tablets relaunched in US

Hyderabad: Dr. Reddy's Laboratories Ltd. has recently announced the re-launch of over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Aleve, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).

"The re-launch of Dr. Reddy's Naproxen Sodium Tablets, 220 mg (OTC), is an important addition to our Pain/Analgesics portfolio of OTC products," says Marc Kikuchi, CEO, North America Generics, Dr. Reddy's Laboratories.

"This launch represents our continued endeavor to leverage our strong capabilities and vertically integrated supply chain on key APls like naproxen to ensure a consistent and reliable supply of finished products for our customers and patients."

Dr. Reddy's OTC Naproxen Sodium Tablets USP, 220 mg is an over-the-counter nonsteroidal anti-inflammatory drug (NSAID) for use as a pain reliever and fever reducer.

It temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, menstrual cramps, headache, toothache, and the common cold; it is also used to temporarily reduce fever.

Dr. Reddy's Naproxen Sodium Tablets USP, 220 mg, will be available in multiple-pack sizes to allow consumers a variety of purchasing options.

Naproxen Sodium Tablets USP, 220 mg, had U.S. retail sales of approximately $316 million as of July 2021 according to IRI*.

Aleve is a trademark of Bayer HealthCare LLC.

Read also: Dr Reddys to provide 2 percent royalty to DRDO on anti-COVID drug 2-DG sale in India